PTO/SB/08b (11-08)
Approved for use through 12/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known		
Substitute for form 1443/FTO	Application Number	10/785,230		
INFORMATION DISCLOSU	RE Filing Date	February 25, 2004		
STATEMENT BY APPLICA	NT First Named Inventor	Tadamitsu Kishimoto	/ %	
(les es manu abosto es necessari)	Art Unit	1642	DEC 0 5 2008	
(Use as many sheets as necessary)	Examiner Name	Laura B. Goddard	2	
Sheet 1 of 1	Attorney Docket Number	046124-5042-01	Pro TRACOURT	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Moore et al. (1998), The Role of CXC Chemokines in the Regulation of Angiogenesis in Association with Lung Cancer, TCMS 8: 51-58.	
	2	Strieter et al. (1995), The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis, J. Biol. Chem. 270: 27348-357.	
,, ,		, .	

Examiner	Date	
Signature	Consid	ered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.